Berlin, Germany – A new initiative aims to shed light on the number of unreported Hepatitis C (HCV) cases, potentially marking a notable step towards better management of the liver disease.
In 2016, the German federal government introduced a Strategy to contain HIV, Hepatitis B and C and other sexually transmitted infections (until 2030), acknowledging advancements in pharmaceutical treatments for this liver disease. Experts involved in the white paper emphasized the need for a clear commitment to elimination, stating that “Germany must ensure a healthy life for all people living here.” The strategy highlighted the absence of a national action plan to coordinate nationwide efforts and “break through infection chains and successfully eliminate the hepatitis C virus.”
Hepatitis C is a viral infection that affects the liver and is transmitted through blood. In approximately 70 percent of cases, the infection can become chronic, potentially leading to liver fibrosis, cirrhosis, liver cancer, and premature death. The presence of the infection can be identified through simple screening and diagnostic tests. as 2014, highly effective modern antiviral medications have been available for the treatment of chronic Hepatitis C.
Further facts can be found at:
Gilead Sciences and AbbVie: The elimination of hepatitis C in Germany. Whitepaper.
Federal ministry of Health: Strategy for containing HIV, hepatitis B and C and other sexually transmitted infections – by 2030.
